Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Aardvark Therapeutics, Inc. (AARD)

Aardvark Therapeutics appoints David Zhang, Ph.D., MBA, to its board of directors

Neutral Impact 2 of 5 leadership Written later

Aardvark Therapeutics appointed David Zhang as a Class II director effective October 7, 2026, and announced the appointment in a press release dated October 8, 2026. The company describes him as an independent director and says he will help navigate the regulatory path for ARD-101 and shape its next phase of development for Prader-Willi Syndrome.

Key points

  • Appointed by the board on October 6, 2026, effective October 7, 2026, as a Class II director
  • Non-employee director cash compensation of $40,000 per year, prorated for time served
  • Option grant on October 7, 2026 sized at $500,000, vesting monthly over 36 months
  • Dr. Zhang is Chief Strategy Officer of Abivax S.A.; previously held roles at Alumis Inc. and MyoKardia, Inc.

The filing

CompanyAardvark Therapeutics, Inc. (AARD)
Form8-K, current report
Filed with the SECOct 8, 2026, 4:14 PM ET
Accession number0001193125-26-417935

Items reported: 5.02 Director / Officer Change8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.